RecruitingEarly Phase 1NCT06488950

A Study of TIL in Advanced Solid Tumors (DFGD)

A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors

Sponsor

Shanghai Juncell Therapeutics

Enrollment

30 participants

Start Date

Apr 1, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Treatment Side Effects Effects of Immunotherapy Tumor Infiltrating Lymphocytes

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called GC203 TIL(gene-edited TIL) or autologous TILs for people with advanced solid tumor, effects of immunotherapy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALGC203 TIL(gene-edited TIL) or autologous TILs

the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample

Locations(1)

Third Affiliated Hospital of Naval Medical University

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06488950

Related Trials

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT057658518 locations

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT0485565622 locations

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

NCT0709829910 locations

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT0612028363 locations

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT0654594218 locations